Nemes Rush Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nemes Rush Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92K	Hold	15	–	–	﹤0.01%	754
2025 Q4	$1.83K	Hold	15	–	–	﹤0.01%	751
2025 Q3	$1.5K	Hold	15	–	–	﹤0.01%	612
2025 Q2	$1.24K	Hold	15	–	–	﹤0.01%	636
2025 Q1	$1.22K	Hold	15	–	–	﹤0.01%	640
2024 Q4	$1.35K	Hold	15	–	–	﹤0.01%	645
2024 Q3	$1.42K	Hold	15	–	–	﹤0.01%	532
2024 Q2	$1.39K	Hold	15	–	–	﹤0.01%	537
2024 Q1	$1.42K	Hold	15	–	–	﹤0.01%	585
2023 Q4	$1.34K	Hold	15	–	–	﹤0.01%	580
2023 Q3	$1.1K	Hold	15	–	–	﹤0.01%	580
2023 Q2	$1.25K	Buy	+15	New	+$1.25K	﹤0.01%	595

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nemes Rush Group's XBI Position: Q1 2026 in Review

Nemes Rush Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 15 shares worth $1.92K. The position accounts for ﹤0.01% of the portfolio, ranked #754.

Nemes Rush Group first reported a position in XBI in Q2 2023 and has held it in 12 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Nemes Rush Group held 15 shares of State Street SPDR S&P Biotech ETF worth $1.92K as of Q1 2026.
Nemes Rush Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #754 holding.
Nemes Rush Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and has held it in 12 quarters since.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.